GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInfra Life Science Inc (XKRX:266470) » Definitions » Cash, Cash Equivalents, Marketable Securities

BioInfra Life Science (XKRX:266470) Cash, Cash Equivalents, Marketable Securities : ₩2,078.9 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioInfra Life Science Cash, Cash Equivalents, Marketable Securities?

BioInfra Life Science's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (₩2,246.84 Mil) to Dec. 2023 (₩492.35 Mil) but then increased from Dec. 2023 (₩492.35 Mil) to Dec. 2024 (₩2,078.91 Mil).

BioInfra Life Science's annual cash, cash equivalents, marketable securities declined from Dec. 2022 (₩2,246.84 Mil) to Dec. 2023 (₩492.35 Mil) but then increased from Dec. 2023 (₩492.35 Mil) to Dec. 2024 (₩2,078.91 Mil).


BioInfra Life Science Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for BioInfra Life Science's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInfra Life Science Cash, Cash Equivalents, Marketable Securities Chart

BioInfra Life Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only 1,556.79 4,485.52 2,246.84 492.35 2,078.91

BioInfra Life Science Semi-Annual Data
Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only 1,556.79 4,485.52 2,246.84 492.35 2,078.91

BioInfra Life Science Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


BioInfra Life Science  (XKRX:266470) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


BioInfra Life Science Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of BioInfra Life Science's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInfra Life Science Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInfra Life Science Inc (XKRX:266470) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
Daehak-ro 49, 7th Floor, Jongno-gu, Seoul, KOR, 03127
BioInfra Life Science Inc is a bio-technology company engaged in developing cancer gene treatments and technologies that systematically monitor the possibility of metastasis and recurrence in blood for cancer patients.

BioInfra Life Science Headlines

No Headlines